Eli Lilly (LLY)
(Delayed Data from NYSE)
$818.93 USD
-10.81 (-1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$818.93 USD
-10.81 (-1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft
Merck to Buy Immunotherapy Developer Immune Design for $300M
by Zacks Equity Research
Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
by Zacks Equity Research
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review
by Swarup Gupta
The index endured a holiday-shortened but volatile week.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Allergan Responds to Investor's Call for CEO/Chair Role Split
by Zacks Equity Research
Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
by Zacks Equity Research
Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.
Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
by Zacks Equity Research
Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.
Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
by Zacks Equity Research
Let us take a look at five favorable stocks, poised to beat estimates this earnings season.
Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down
by Zacks Equity Research
Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report
by Zacks Equity Research
Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod
by Zacks Equity Research
J&J (JNJ) gets FDA advisory committee's positive recommendation for its investigational nasal spray, Spravato (esketamine) for treatment-resistant depression in adults.
The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion
5 Tiny Biotech Stocks With Superb Growth Potential
by Swarup Gupta
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Eli Lilly (LLY) and U.S. Bancorp (USB).
Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake
by Zacks Equity Research
Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
by Zacks Equity Research
The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
by Zacks Equity Research
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Stock Market News For Feb 7, 2019
by Zacks Equity Research
U.S. stocks closed lower on Wednesday following disappointing earnings results from videogame companies.
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
by Zacks Equity Research
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.